Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. - sprookjes - yvandenbroek - TriplyDB

Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.

Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.

http://www.wikidata.org/entity/Q37387345

about

Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination Chemotherapy Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting.Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting Antiemetics: American Society of Clinical Oncology clinical practice guideline update.Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)Treatment of Chemotherapy-Induced Nausea in Cancer Patients.Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy.Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting.Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting Palonosetron exhibits higher total control rate compared to first-generation serotonin antagonists and improves appetite in delayed-phase chemotherapy-induced nausea and vomiting.A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting Olanzapine: palliative medicine update.Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.Meta-analysis of adjunctive non-NK1 receptor antagonist medications for the control of acute and delayed chemotherapy-induced nausea and vomiting.Palonosetron for the treatment of chemotherapy-induced nausea and vomiting.Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review.Olanzapine in the treatment of refractory nausea and vomiting: a case report and review of the literature.Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.State of the Art Antiemetic Therapy for Cancer Patients.The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting.Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy.Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy.Antiemetic research: future directions.Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study.A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist.Carbamazepine for prevention of chemotherapy-induced nausea and vomiting: a pilot study.

P2860

Q26783177-23D20853-0B5B-4B59-9999-C483493FF16C Q26784070-D025DD51-C30A-404F-B9B7-2AE854141B01 Q28081186-17A40D29-3A6E-4A87-AFA6-A7229E897C5B Q30235971-80CDB837-5A01-4B0B-8CFF-543258FDC5DE Q33834310-50709718-02AE-4DAF-9A68-A58C450AE674 Q33866119-9D360D2D-94E9-4483-A9AB-B6B454BC7203 Q33886138-41378730-8051-4C19-BB10-03C16414AC47 Q34030613-FA016E36-BC5F-4A56-82B3-20CE4DD05BAE Q34775395-D63FFD24-FD21-453C-91F1-EACE1B997FF8 Q35282520-283813F2-95CF-4426-A302-4AC49E99396A Q35789229-7E9ED2DC-7AB1-43B7-BC90-F1CF09A97173 Q36070497-3B876D07-E14F-4F20-A3ED-4218BE460604 Q37669043-A4853F0D-0ABC-45E4-854D-042B2D041D33 Q37691654-A18D7BBC-9E99-4DAD-BF2E-0A0F0D328897 Q37722200-9C35FF50-ADDB-4048-9A07-DFC98409B8FE Q37738165-6CC4562F-1D94-4CFB-8B61-1AD9923159A4 Q38001959-5E239EF4-63D6-4191-A95E-637189916804 Q38187578-DF43F0EA-824E-46A3-ACA2-3846C8830074 Q38241998-1CA9484C-5C3A-4A0B-8D58-2D3CE5EF4F6C Q38260952-F3DC9288-4326-458B-A29B-B955909504AF Q38261290-95E39E93-9942-4263-AEC2-463D474E1DD3 Q38533535-86E8DD7D-D9AE-4329-8003-922A79EA9659 Q38574240-68DA77E0-D478-465C-814C-A40717626A56 Q38676452-5B1D9684-4CBF-4976-876A-E65334A8CE5C Q38677762-2A0DE8BA-CB94-4A53-9930-A140793BEBF1 Q38696953-326B1A0B-87A3-49F9-8778-30E12F0C89E2 Q38739169-EE015C99-0BBC-4289-83DF-0653B5E25892 Q38786773-7472C713-09B5-4AD7-A67E-BA8CE5DAEA34 Q38904462-CDC94577-7B3E-42DE-B74F-BDF1279254FC Q39005867-76F3A9FF-A33D-4289-8783-9F3C34E416F0 Q39160097-A708B4B9-02FE-4DA1-8E7C-887EEDAC094F Q39213490-5A240D91-5F83-41AB-9CBE-1CB6201537DC Q39818791-35721A3C-DBF9-4242-B017-EC6EFF53F5A0 Q40542547-BBC94E37-4589-4C29-84A3-9C822F67D86F Q40825770-4ED35C8F-6F2D-4397-B85D-FCAB34896E67 Q47664267-4F92EB77-E5AB-4A95-B636-8CA3E6FFA33A Q47741649-0DD0A2AC-C6A3-4F00-A085-3FA7569DE517 Q47856901-A69E2D77-2EBF-4A06-A37D-A9354BE62349 Q48016196-7B45E576-FD1A-4ACB-B8C5-19CDBB170C13 Q48078956-69FDC3CD-4AF7-4493-B173-1A4F39C3BE7A

P2860

Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.

http://www.wikidata.org/entity/Q37387345

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 September 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical research of Olanzapin ...... y-induced nausea and vomiting.

@en

Clinical research of Olanzapin ...... y-induced nausea and vomiting.

@nl

type

label

Clinical research of Olanzapin ...... y-induced nausea and vomiting.

@en

Clinical research of Olanzapin ...... y-induced nausea and vomiting.

@nl

prefLabel

Clinical research of Olanzapin ...... y-induced nausea and vomiting.

@en

Clinical research of Olanzapin ...... y-induced nausea and vomiting.

@nl

P1433

Q37387345-89A34CF4-1AF1-49BE-BBD4-8B875175E362

P1476

Q37387345-D8143471-ADB6-493D-B440-77497C67DC5E

P2093

Q37387345-130E4E5E-584C-4B62-8F6D-483D3E1B0524

Q37387345-1835FBDE-2CB8-459E-8613-AAFD4FC4024E

Q37387345-44DE4244-879A-4664-89C6-4A9102B6A83B

Q37387345-496C6259-57FC-4E5A-94FB-40828B863D52

Q37387345-A8EC4F3C-43BC-4B96-BD53-20588D9A94F0

Q37387345-A8F3D040-80F2-4E18-9B97-80A603D64D05

Q37387345-E46E3903-80FB-4236-A819-BC39B43E3E17

P2860

Q37387345-01B94B15-269A-4E54-8B31-0BBF240A70EB

Q37387345-04024F30-D491-47CA-818A-B7FE9D5F1A6F

Q37387345-159594DD-8DA9-46F8-9538-32FAEF4EA992

Q37387345-29C6C917-B730-4097-9E85-08E1FF44964A

Q37387345-2EB19F3C-CED4-4656-97E7-A8328CEBADC3

Q37387345-361E2C08-C0A5-45F8-92A6-CA155D869246

Q37387345-42ADB733-E318-49DA-AF12-F20A2D0391E7

Q37387345-4F3C938B-C6B1-4591-8ACA-C88147DC1E71

Q37387345-5314A95E-7E32-4D28-879E-2F07FAF2CC44

Q37387345-80E39D26-79C4-4B35-A987-C5F964F1B7FA

P2888

Q37387345-FC3027A3-CBCA-445B-B4A5-5030BB2DE142

P304

Q37387345-DBC7B031-A77E-47F1-ADD9-91711E93056C

P31

Q37387345-29583930-29DB-476D-8F06-E22A72B27AA9

P356

Q37387345-6F0AE547-1A51-42F9-920E-B46C07E5376D

P478

Q37387345-A5416F56-0E29-4573-930B-82415C914712

P577

Q37387345-3CA52160-F82C-4239-9889-D43F3B8BD6A2

P5875

Q37387345-66E88801-41AD-4BC9-8DEE-3BF2CFDDA7A0

P6179

Q37387345-827F4368-146C-4388-A055-84CE40856817

P698

Q37387345-B28A8EFD-5536-4916-8F3D-6FA000C82B53

P921

Q37387345-D36786BF-2FE9-4695-9EA1-0F447A84AAA7

P932

Q37387345-15CC90C0-E761-48DF-8221-4FA48697C055

P356

1756-9966-28-131

P1433

Journal of Experimental & Clinical Cancer Research

P1476

Clinical research of Olanzapin ...... y-induced nausea and vomiting.

@en

P2093

Daxin Zhang

http://www.w3.org/2001/XMLSchema#string

Huifen Yang

http://www.w3.org/2001/XMLSchema#string

Jiangtao Liu

http://www.w3.org/2001/XMLSchema#string

Jie Chen

http://www.w3.org/2001/XMLSchema#string

Lijun Tan

http://www.w3.org/2001/XMLSchema#string

Xiuli Liu

http://www.w3.org/2001/XMLSchema#string

Zhijun Yan

http://www.w3.org/2001/XMLSchema#string

P2860

A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients.

Delayed emesis: moderately emetogenic chemotherapy.

Acute emesis: moderately emetogenic chemotherapy.

Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update.

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy.

A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain.

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.

Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer.

P2888

1756-9966-28-131

P304

131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1756-9966-28-131

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26832633

http://www.w3.org/2001/XMLSchema#string

P6179

1034601976

http://www.w3.org/2001/XMLSchema#string

P698

19775450

http://www.w3.org/2001/XMLSchema#string

P921

P932

2761865

http://www.w3.org/2001/XMLSchema#string